Research programme: Parkinson's disease therapeutics - Alectos Therapeutics

Drug Profile

Research programme: Parkinson's disease therapeutics - Alectos Therapeutics

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alectos Therapeutics; Simon Fraser University
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Glucosylceramidase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Parkinson's disease

Most Recent Events

  • 11 Feb 2016 Early research in Parkinson's disease in Canada before February 2016 (Alectos Therapeutics pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top